MedTrace Logo

A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

NCT05612633 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-11-10

No results posted yet for this study

Summary

This is a multicenter, Phase 2 Simon 2-Stage study designed to assess the safety, tolerability, PK, and efficacy of oral zelavespib (PU-H71) administered daily in adults with accelerated phase (10% to 19% blasts in peripheral or bone marrow) myeloproliferative neoplasm, with or without ongoing concomitant treatment with ruxolitinib.

Conditions

  • Accelerated Phase MPN
  • Blast Phase MPN

Interventions

DRUG

zelavespib

Oral zelavespib 100 mg will be administered once daily

Sponsors & Collaborators

  • Samus Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-12-15
Completion
2024-02-23
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05612633 on ClinicalTrials.gov